Your search returned 464 results.

Results
	421.	New drugs 2015, part 2. [electronic resource] by Hussar, Daniel A Producer: 20160104 In: Nursing vol. 45 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	422.	Identification of Patient Characteristics Influencing Setting of Care Decisions for Patients With Acute Bacterial Skin and Skin Structure Infections: Results of a Discrete Choice Experiment. [electronic resource] by Lane, Suzanne Johnston, Karissa Sulham, Katherine A Syed, Iqra Pollack, Charles V Holland, Thomas Nathwani, Dilip Producer: 20161107 In: Clinical therapeutics vol. 38 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	423.	Use of telavancin in adolescent patients with cystic fibrosis and prior intolerance to vancomycin: A case series. [electronic resource] by Bernstein, Adam T Leigh, Margaret W Goralski, Jennifer L Esther, Charles R McKinzie, Cameron J Producer: 20191114 In: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society vol. 17 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	424.	Acute bacterial skin and skin structure infections in internal medicine wards: old and new drugs. [electronic resource] by Falcone, Marco Concia, Ercole Giusti, Massimo Mazzone, Antonino Santini, Claudio Stefani, Stefania Violi, Francesco Producer: 20170912 In: Internal and emergency medicine vol. 11 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	425.	On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections. [electronic resource] by Morrisette, Taylor Miller, Matthew A Montague, Brian T Barber, Gerard R McQueen, R Brett Krsak, Martin Producer: 20200812 In: The Journal of antimicrobial chemotherapy vol. 74 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	426.	Resistance to vancomycin, LY333328, ciprofloxacin and trovafloxacin of community-acquired and nosocomial strains of Enterococcus faecalis isolated in Badajoz (Spain) with and without high-level resistance to streptomycin and gentamicin. [electronic resource] by Sánchez-Silos, R M Pérez-Giraldo, C Blanco, M T Morán, F J Hurtado, C Gómez-García, A C Producer: 20020226 In: Chemotherapy vol. 47 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	427.	Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. [electronic resource] by Shaw, J P Seroogy, J Kaniga, K Higgins, D L Kitt, M Barriere, S Producer: 20050222 In: Antimicrobial agents and chemotherapy vol. 49 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	428.	Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus. [electronic resource] by Belley, Adam Neesham-Grenon, Eve Arhin, Francis F McKay, Geoffrey A Parr, Thomas R Moeck, Gregory Producer: 20090109 In: Antimicrobial agents and chemotherapy vol. 52 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	429.	Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections. [electronic resource] by Roberts, Karrine D Sulaiman, Rand M Rybak, Michael J Producer: 20160815 In: Pharmacotherapy vol. 35 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	430.	Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis. [electronic resource] by Kussmann, Manuel Karer, Matthias Obermueller, Markus Schmidt, Katy Barousch, Wolfgang Moser, Doris Nehr, Marion Ramharter, Michael Poeppl, Wolfgang Makristathis, Athanasios Winkler, Stefan Thalhammer, Florian Burgmann, Heinz Lagler, Heimo Producer: 20190422 In: Emerging microbes & infections vol. 7 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	431.	Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus. [electronic resource] by Corey, G Ralph Arhin, Francis F Wikler, Matthew A Sahm, Daniel F Kreiswirth, Barry N Mediavilla, José R Good, Samantha Fiset, Claude Jiang, Hai Moeck, Greg Kabler, Heidi Green, Sinikka O'Riordan, William Producer: 20170306 In: International journal of antimicrobial agents vol. 48 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	432.	Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis. [electronic resource] by Cabellos, Carmen Fernàndez, Antonio Maiques, Jose M Tubau, Fe Ardanuy, Carmen Viladrich, Pedro F Liñares, Josefina Gudiol, Francesc Producer: 20031007 In: Antimicrobial agents and chemotherapy vol. 47 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	433.	Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. [electronic resource] by Seral, Cristina Van Bambeke, Françoise Tulkens, Paul M Producer: 20030814 In: Antimicrobial agents and chemotherapy vol. 47 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	434.	In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies. [electronic resource] by Krause, Kevin M Barriere, Steven L Kitt, Michael M Benton, Bret M Producer: 20110125 In: Diagnostic microbiology and infectious disease vol. 68 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	435.	Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality. [electronic resource] by Lacy, Melinda K Stryjewski, Martin E Wang, Whedy Hardin, Thomas C Nogid, Boris Luke, David R Shorr, Andrew F Corey, G Ralph Barriere, Steven L Producer: 20160609 In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. 61 Suppl 2 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	436.	Telavancin for refractory MRSA bacteraemia in intermittent haemodialysis recipients. [electronic resource] by Britt, Nicholas S Tirmizi, Samad Ritchie, David J Topal, Jeffrey E McManus, Dayna Nizet, Victor Casabar, Ed Sakoulas, George Producer: 20190423 In: The Journal of antimicrobial chemotherapy vol. 73 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	437.	Telavancin: the long and winding road from discovery to food and drug administration approvals and future directions. [electronic resource] by Wenzler, Eric Rodvold, Keith A Producer: 20160609 In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. 61 Suppl 2 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	438.	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus. [electronic resource] by Miró, José M García-de-la-Mària, Cristina Armero, Yolanda de-Lazzari, Elisa Soy, Dolors Moreno, Asunción del Rio, Ana Almela, Manel Mestres, Carlos A Gatell, José M Jiménez-de-Anta, María-Teresa Marco, Francesc Producer: 20071030 In: Antimicrobial agents and chemotherapy vol. 51 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	439.	A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. [electronic resource] by Stryjewski, Martin E Lentnek, Arnold O'Riordan, William Pullman, John Tambyah, Paul Anantharajah Miró, Jose M Fowler, Vance G Barriere, Steven L Kitt, Michael M Corey, G Ralph Producer: 20150623 In: BMC infectious diseases vol. 14 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	440.	Time Course and Extent of Renal Function Changes in Patients Receiving Treatment for Staphylococcal Pneumonias: An Analysis Comparing Telavancin and Vancomycin from the ATTAIN Trials. [electronic resource] by Nogid, Boris Lacy, Melinda K Jacobs, Micah Bruss, Jon Dwyer, Jamie Producer: 20190829 In: Pharmacotherapy vol. 38 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)

First
Previous
13
14
15
16
17
18
19
20
21
22
23
24
Next
Last

Refine your search

Availability

Authors

Topics

Languages

Your search returned 464 results.